Table 5.
Prevalence of CMBs in population-based studies
| Study | Population | Number | Age (yr) | MRI parameters |
CMB (%) | |
|---|---|---|---|---|---|---|
| Sequence | Field strength (Tesla) | |||||
| ASPS (1999) [19] | Austria | 280 | 60±6 | 2D T2* GRE | 1.5 | 6.4 |
| Japanese Study (2002) [20] | Japan | 450 | 53±8 | 2D T2* GRE | 1.0 | 3.1 |
| AGES Reykjavik Study (2008) [21] | Iceland | 1,962 | 76±6 | 2D T2* GRE | 1.5 | 11.1 |
| RSS (2010) [12] | Netherlands | 3,979 | 60±9 | 3D T2* GRE | 1.5 | 15.3 |
| FHS (2014) [22] | USA | 1,965 | 66±11 | 2D T2* GRE | 1.0 | 8.8 |
| EDIS (2017) [2] | Singapore | 832 | 70±6 | SWI | 3.0 | 34.4 |
| RISK (2017) [2] | Hong Kong | 850 | 71±5 | 2D T2* GRE | 3.0 | 21.1 |
| OBAMA (2017) [2] | Korea | 115 | 65±5 | 2D T2* GRE | 3.0 | 13 |
| Shunyi Study (2017) | China | 1,211 | 56±9 | SWI | 3.0 | 10.6 |
Values are presented as mean±SD.
CMB, cerebral microbleed; MRI, magnetic resonance imaging; ASPS, Austrian Stroke Prevention Study; 2D, 2-dimensional; GRE, gradient-recalled echo; AGES, Age, Gene/Environment Susceptibility; RSS, Rotterdam Scan Study; 3D, three-dimensional; FHS, Framingham Heart Study; EDIS, Epidemiology of Dementia in Singapore study; SWI, susceptibility-weighted image; RISK, Risk Index for Subclinical brain lesions in Hong Kong study; OBAMA, Oligomeric Beta Amyloid detection by Multimer detection system in Alzheimer’s disease study.